Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Chlorphenoxamine. |
| Mirabegron | The risk or severity of urinary retention can be increased when Chlorphenoxamine is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Chlorphenoxamine is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Chlorphenoxamine. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Chlorphenoxamine. |
| Tiotropium | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorphenoxamine is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Umeclidinium. |
| Benzylpenicilloyl polylysine | Chlorphenoxamine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorphenoxamine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorphenoxamine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorphenoxamine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum toxin type A. |
| Glucagon | Chlorphenoxamine may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Chlorphenoxamine may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Chlorphenoxamine is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Chlorphenoxamine is combined with Ramosetron. |
| Amphetamine | Amphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Phentermine | Phentermine may decrease the sedative activities of Chlorphenoxamine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Chlorphenoxamine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Chlorphenoxamine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Chlorphenoxamine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Chlorphenoxamine. |
| MMDA | MMDA may decrease the sedative activities of Chlorphenoxamine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Chlorphenoxamine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorphenoxamine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Chlorphenoxamine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Chlorphenoxamine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Chlorphenoxamine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Chlorphenoxamine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Chlorphenoxamine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Chlorphenoxamine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Chlorphenoxamine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Chlorphenoxamine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorphenoxamine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Chlorphenoxamine. |
| Tramadol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tramadol. |
| Methadone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadone. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levacetylmethadol. |
| Morphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine. |
| Naltrexone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Diamorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Bezitramide. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Chlorphenoxamine is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Chlorphenoxamine. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Chlorphenoxamine. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Chlorphenoxamine. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Chlorphenoxamine. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Chlorphenoxamine. |